Surveyed Top 50 Pharma and Biotech Companies Report Average Per-Patient Costs of $57,500 During Non-Adaptive Phase 1 Studies
March 27, 2017 19:28 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - March 27, 2017) - Surveyed pharmaceutical, biotech, and device companies expend up to $120,000 per patient during Phase 1 non-adaptive studies, according to...
Heightened Demand for R&D Innovation May Prompt BioPharma Industry Groups to Seek Academic Partnerships
March 14, 2017 07:38 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - March 14, 2017) - Throughout the research and development process, third-party organizations have helped pharmaceutical, biotech and medical device teams to...
R&D Comprises an Average of 64% of Preclinical Teams' Internal Clients, Finds New Business Intelligence Study
March 07, 2017 07:34 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - March 07, 2017) - A new study of early-stage product development teams found that, on average, R&D comprises 64% of the internal clients that surveyed...
Centralized Adaptive Trial Design Teams Promote Cross-Geography Communication
December 07, 2016 08:36 ET
|
Cutting Edge Information
RESEARCH TRIANGLE PARK, NC--(Marketwired - December 07, 2016) - A recent study released by Cutting Edge Information found that most surveyed clinical trial teams -- either global or at the country...
INC Research Receives 2016 Frost & Sullivan Asia Pacific Contract Research Outsourcing Services Customer Value Leadership Award
October 24, 2016 08:30 ET
|
INC Research, LLC
RALEIGH, N.C., Oct. 24, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization, today announced it has been awarded the...
INC Research Announces Secondary Offering
August 01, 2016 06:43 ET
|
INC Research, LLC
RALEIGH, N.C., Aug. 01, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR) (the “Company”), a leading global Phase I to Phase IV contract research organization, today announced...
INC Research Expands Presence in Japan with New Osaka Office
May 25, 2016 08:00 ET
|
Syneos Health, Inc.
RALEIGH, N.C., May 25, 2016 (GLOBE NEWSWIRE) -- INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization (CRO), today announced the relocation and...
ISR Projects Continued Growth Propelling the CRO Market Forward
February 02, 2016 11:56 ET
|
Industry Standard Research
CARY, NC--(Marketwired - February 02, 2016) - Industry Standard Research (ISR) today announced a new addition to its Market Analysis suite of reports. The "2016 Edition of the CRO Market Size...
OnCore Biopharma Closes Series R Financing
September 05, 2014 07:00 ET
|
OnCore Biopharma, Inc.
Funds to Expand OnCore's Portfolio of Oral Therapeutics for the Treatment of Chronic HBV
OnCore to Advance HBV Compounds Into Phase 1 Clinical Development During 2015
Former Pharmasset Team...
Advinus Therapeutics and P2D Bioscience Enter Into a Research and Development Collaboration for Attention Deficit Hyperactivity Disorder (ADHD)
July 24, 2012 08:35 ET
|
P2D Bioscience
CINCINNATI, OH and BANGALORE, INDIA--(Marketwire - Jul 24, 2012) - Advinus Therapeutics Ltd., a drug discovery and development company, and P2D Bioscience, a CNS-focused specialty...